AAUM (Average Assets Under Management) of ₹3,699.49 Cr for Jul-Sep 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 66.4% | 65.0% | ▼ -1.5% |
| Healthcare Services | 20.4% | 17.8% | ▼ -2.5% |
| Insurance | 1.0% | 1.0% | ● +0.0% |
| Healthcare Equipment & Supplies | 0.1% | 0.1% | ● 0.0% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 65.0% | 65.2% | ▲ +0.2% |
| Healthcare Services | 17.8% | 20.8% | ▲ +3.0% |
| Healthcare Equipment & Supplies | 0.1% | 1.3% | ▲ +1.1% |
| Insurance | 1.0% | 1.0% | ● 0.0% |
Comparing Sep 2026 → Oct 2026
| # | Stock | Sector | Weight (Oct 2026) |
|---|---|---|---|
| 1 | Sahajanand Medical Technologies Limited ₹41.76 Cr |
Healthcare Equipment & Supplies | 1.12% |
| # | Stock | Sector | Sep 2026 | Oct 2026 | Change |
|---|---|---|---|---|---|
| 1 | Apollo Hospitals Enterprise Limited ₹293.96 Cr |
Healthcare Services | 6.07% | 7.89% | +1.82% |
| 2 | Thyrocare Technologies Limited ₹105.83 Cr |
Healthcare Services | 1.91% | 2.84% | +0.93% |
| 3 | Abbott India Limited ₹42.42 Cr |
Pharmaceuticals & Biotechnology | 0.26% | 1.14% | +0.88% |
| 4 | Eris Lifesciences Limited ₹44.73 Cr |
Pharmaceuticals & Biotechnology | 0.72% | 1.20% | +0.48% |
| 5 | Gland Pharma Limited ₹246.21 Cr |
Pharmaceuticals & Biotechnology | 6.15% | 6.61% | +0.46% |
| 6 | Syngene International Limited ₹65.61 Cr |
Healthcare Services | 1.35% | 1.76% | +0.41% |
| 7 | Divi's Laboratories Limited ₹164.52 Cr |
Pharmaceuticals & Biotechnology | 4.17% | 4.41% | +0.24% |
| 8 | Cipla Limited ₹275.97 Cr |
Pharmaceuticals & Biotechnology | 7.18% | 7.40% | +0.22% |
| 9 | Procter & Gamble Health Limited ₹90.32 Cr |
Pharmaceuticals & Biotechnology | 2.36% | 2.42% | +0.06% |
| 10 | Cohance Lifesciences Limited ₹142.31 Cr |
Pharmaceuticals & Biotechnology | 3.79% | 3.82% | +0.03% |
| # | Stock | Sector | Sep 2026 | Oct 2026 | Change |
|---|---|---|---|---|---|
| 1 | IPCA Laboratories Limited ₹279.12 Cr |
Pharmaceuticals & Biotechnology | 8.13% | 7.49% | -0.64% |
| 2 | Indoco Remedies Ltd ₹67.61 Cr |
Pharmaceuticals & Biotechnology | 2.26% | 1.81% | -0.45% |
| 3 | Sai Life Sciences Limited ₹229.79 Cr |
Pharmaceuticals & Biotechnology | 6.52% | 6.17% | -0.35% |
| 4 | Concord Biotech Limited ₹91.65 Cr |
Pharmaceuticals & Biotechnology | 2.70% | 2.46% | -0.24% |
| 5 | Unichem Laboratories Ltd. ₹54.67 Cr |
Pharmaceuticals & Biotechnology | 1.64% | 1.47% | -0.17% |
| 6 | Sun Pharmaceutical Industries Limited ₹272.98 Cr |
Pharmaceuticals & Biotechnology | 7.44% | 7.32% | -0.12% |
| 7 | Pfizer Limited ₹97.22 Cr |
Pharmaceuticals & Biotechnology | 2.72% | 2.61% | -0.11% |
| 8 | Alembic Pharmaceuticals Limited ₹115.09 Cr |
Pharmaceuticals & Biotechnology | 3.18% | 3.09% | -0.09% |
| 9 | Manipal Health Enterprises Ltd ₹65.58 Cr |
Healthcare Services | 1.85% | 1.76% | -0.09% |
| 10 | Nephrocare Health Services Ltd ₹39.02 Cr |
Healthcare Services | 1.12% | 1.05% | -0.07% |
28 stocks — Oct 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹293.96 Cr |
Healthcare Services |
7.89%
|
|
| 2 |
₹279.12 Cr |
Pharmaceuticals & Biotechnology |
7.49%
|
|
| 3 |
₹275.97 Cr |
Pharmaceuticals & Biotechnology |
7.40%
|
|
| 4 |
₹272.98 Cr |
Pharmaceuticals & Biotechnology |
7.32%
|
|
| 5 |
₹246.21 Cr |
Pharmaceuticals & Biotechnology |
6.61%
|
|
| 6 |
₹229.79 Cr |
Pharmaceuticals & Biotechnology |
6.17%
|
|
| 7 |
₹176.24 Cr |
Pharmaceuticals & Biotechnology |
4.73%
|
|
| 8 |
₹164.52 Cr |
Pharmaceuticals & Biotechnology |
4.41%
|
|
| 9 |
₹142.31 Cr |
Pharmaceuticals & Biotechnology |
3.82%
|
|
| 10 |
₹115.09 Cr |
Pharmaceuticals & Biotechnology |
3.09%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.